New Delhi: US pharma major Eli Lilly & Co expressed disappointment over decision of drug price controller NPPA to fix price of medicines that are not under price control, and called for a transparent consultative approach with all stakeholders before taking such a step. “We are surprised and disappointed by this unexpected action,” Eli Lilly and Co India MD Edgard A Olaizola said.